达雷妥尤单抗、硼替佐米和地塞米松用于多发性骨髓瘤首次复发患者:英国多中心真实世界回顾性分析
该英国15中心回顾性分析纳入296例首次复发多发性骨髓瘤患者,接受达雷妥尤单抗、硼替佐米和地塞米松(DVd)周疗方案。中位随访21个月,总缓解率82%,中位无进展生存期16个月(95%CI 12-20),2年总生存率74%,2-3级周围神经病变发生率7%。高危特征及早期进展患者结局显著较差。
要点
- DVd周疗方案在首次复发多发性骨髓瘤真实世界中总缓解率82%,中位无进展生存期16个月。
- 2-3级周围神经病变发生率仅7%,安全性可控。
- 高危细胞遗传学、ISS或髓外病变及早期进展患者结局显著较差,应考虑替代治疗。
核心结论
- DVd周疗方案在异质性真实世界首次复发多发性骨髓瘤人群中有效,周围神经病变发生率低。
- 高危特征患者及早期进展患者结局较差,应考虑替代治疗。
研究设计与样本
- 英国15个中心回顾性多中心分析,纳入296例连续首次复发多发性骨髓瘤患者,接受DVd周疗方案。
主要发现
- 中位随访21个月,总缓解率82%(部分缓解26%,非常好的部分缓解及以上56%)。
- 中位无进展生存期16个月(95%CI 12-20个月),中位至下一次治疗时间20个月(95%CI 15-25个月)。
- 2年估计总生存率74%。
- 无论既往是否暴露来那度胺,结果相似。
- 高危特征(细胞遗传学、国际分期系统或髓外病变)患者及无进展治疗开始后18个月内或自体干细胞移植后12个月内治疗的患者结局显著较差。
临床怎么用
- DVd周疗方案可用于首次复发多发性骨髓瘤真实世界人群。
- 高危特征患者及早期进展患者应考虑替代治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Daratumumab, bortezomib and dexamethasone (DVd) is approved for patients with relapsed multiple myeloma following the CASTOR phase 3 clinical trial. This retrospective multicentre analysis assesses the overall response rate (ORR) and progression-free survival (PFS) in routine clinical practice for patients at first relapse treated with DVd incorporating weekly bortezomib. Data were collected from 296 sequential patients treated across 15 UK centres. After a median follow-up of 21 months, the ORR was 82% (26% partial response, 56% very good partial response or better) and the median PFS was 16 months [95% confidence interval (CI) 12-20 months]. Results were similar regardless of prior lenalidomide exposure. The median time to next treatment was 20 months (95% CI 15-25 months) and the estimated overall survival at two years was 74%. Patients with high-risk features (by cytogenetics, International Staging System or extramedullary disease) and those treated within 18 months of initiation of progression-free treatment, or within 12 months of autologous stem cell transplant, had significantly inferior outcomes. The grade 2 and 3 peripheral neuropathy rate was 7%. DVd with weekly bortezomib was effective in a heterogenous real-world population at first relapse with a low rate of peripheral neuropathy. However, high-risk patients had inferior outcomes and should be considered for alternative treatments.
引用
- McMillan A, Basu S, Karunanithi K, et al. Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis. Br J Haematol. 2023. PMID: 36822820. doi:10.1111/bjh.18703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。